MediGene to continue trial of oncolytic virus to treat liver metastases

By Elaine Rigoli

Tampa, Fla., Sept. 15 - Biotech company MediGene AG said an interim analysis of the phase 1/ 2 trial of the cancer-killing virus NV1020 for the treatment of liver metastases in patients suffering from colorectal carcinoma has shown a clear indication of efficacy.

The Martinsried, Germany, and San Diego-based company therefore said the trial will be continued as scheduled, with the maximum dosage of the viruses.

In the first stage of the trial, 13 patients whose cancer was progressing despite treatment with chemotherapeutics and monoclonal antibodies were medicated with oncolytic viruses in different concentration. A total of four virus injections was administered at weekly intervals through the hepatic artery into the patients' livers affected by metastases.

Imaging techniques, clinical appearance, as well as blood analyses, verify that the viruses have a dose dependent therapeutic effect in the patients treated, according to a news release.

All patients receiving the maximum dosage showed either a disease stabilization or even a clear regression of liver metastases, the release said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.